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The role of regulatory B cells on hepatocellular carcinoma progression  
Conclusion  
Results 
Fig2. (A and B) In vivo, Bregs in SCID mice increased the size of HCC tumor time-dependently. 
(C)In vivo imagining showed that Bregs could migrate into tumor site. * p<0.05 ; ** p<0.01 
Tumors were stained by Qdot705 (green); Bregs were stained by DiR (red). (D) Bregs were 
detected in the tumor region. 
Y Shao, CM Lo, CC Ling, XB Liu, KTP Ng, J Guo, YY Ma, CX Li, ST Fan and K Man 
Department of Surgery, The University of Hong Kong, Hong Kong  
Materials and methods 
 Clinic study: abundance of circulating Bregs, the distribution of B cells in 
tumor tissues of HCC patients and their clinical correlation. 
  In vitro study: the role of Bregs on HCC growth and migration in 
coculture system   
 In vivo study: the role of Bregs on HCC growth further using SCID mice 
liver cancer model 
Numbers of patients, median (range) and p-values were presented as shown in table.   * p<0.05 ; ** p<0.01 
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Background 
Hepatocellular carcinoma (HCC) is one of the most common cancers worldwide with 
a poor prognosis of limited survival. Human regulatory Breg cells(Bregs), a new 
subset of B cells, play an important role in autoimmune disease. However, the role of 
Bregs in the HCC progression and the underlying mechanisms is still unknown. 
•Abundance of B cells at HCC tumor margin was associated with cancer progression. 
•Circulating regulatory B cells (Bregs) were associated with HCC progression. 
Clinicopathological 
parameters 
Circulating Bregs per (105 PBLs ) p-value 
Tumor size <5 cm (n=40) ≥5 cm (n=34)   
289.6 (12.96-2868.08) 419.5 (56.83-2938.22) 0.15 
Tumor multiplicity simple (n=66) multiply (n=8)   
333.8 (12.96-2938.22) 
1072 (165.87-
2080.87) 
0.023*  
Encapsulation absent (n=66) present (n=8)   
  347.7 (12.96-2938.22) 1027 (25.67-1829.73) 0.102 
Venous infiltration absent (n=36) present (n=38)   
 319.5 (18.2-1900.1) 433.6 (12.96-2938.22) 0.029*  
UICC stages early (n=57) late (n=17)   
305 (12.96-2860.08) 606.4 (56.83-2938.22) 0.019*  
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Objective 
 To study the roles of Bregs in liver tumor growth and invasion 
 To investigate the underneath mechanisms of Bregs regulating HCC progression 
1. Human intrahepatic B cells and peripheral B cell subsets 
participated in HCC progression.  
Clinicopathological 
parameters 
B cells in tumor margin, % p-value 
Tumor size (cm) <5 (n=7) ≥5 (n=52)   
  3.81 (0.41-12.88) 5.22 (0.75-16.38) 0.004*  
Tumor multiplicity simple (n=48) multiply (n=11)   
5.07 (0.41-16.38) 6.18 (1.61-11.4) 0.263 
Encapsulation  absent (n=53) present (n=6)   
5.26 (0.41-16.38) 4.38 (1.22-5.68) 0.029*  
Venous infiltration absent (n=20) present (n=39)   
 2.63 (0.41-16.38) 5.68 (1.53-13.26) 0.006*  
UICC stages early (n=27) late (n=32)   
4.92 (0.41-12.88) 5.42 (1.53-16.38) 0.025*  
Table. Association between intrahepatic B cells or circulating Bregs 
and the clinicopathological parameters of HCC patients.  
Fig1. (A and B) higher number of CD20 positive B cells were found at tumor margin of advanced 
HCC tumors. NT: non-tumor region, M: tumor margin region, T: tumor region. (C) B cells were 
increased with the advance of TNM stages of HCC. (D and E ) A significantly higher percentage of 
Bregs and lower percentage of memory B cells from bloods of HCC patients than that from 
normal bloods was founded in HCC patients.(F ) The number of Bregs per 105 PBLs was increased 
with progressive stages of HCC patients. 
2. Human Bregs engrafted in SCID mice and promoted tumor growth.  
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3. Bregs promoted proliferation and invasion of HCC cells. 
Fig3. (A) Luciferase-labeled human HCC cell line MHCC-97L cells were cocultured with B 
cells or Bregs. Bregs could promote more MHCC-97L cells proliferation than B cells. (B) 
Apoptotic assay demonstrated that the percentages of late apoptotic MHCC-97L cells 
were decreased after coculture with Bregs. (C) The number of invaded MHCC-97L cells 
was increased after coculturing with Bregs compare to coculturing with B cells. 
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4. CD154 neutralization abolished Bregs induced tumor growth. 5.Bregs interacted with HCC cells through CD40-CD154 signaling. 
Fig5. (A and B) Bregs induced MHCC-97L cells to express high level of CD40 and CD154 protein. (C) Bregs could 
promote MHCC-97L cells proliferation. Anti-CD154 neutralizing antibody reversed the induction of HCC 
proliferation by Bregs. (D) Human TNF-α secretion was decreased concurrently with the induction of HCC cell 
proliferation. (E) IL10 secretion was highly induced in Bregs-HCC cells coculture. (F and G)The expression of 
human active and total TGF-β1 was measured.  
Fig4. HCC tumor growth was faster in Bregs group than non-Bregs injection or HCC control group. In 
addition, the Bregs induced tumor growth was inhibited by anti-CD154 neutralizing antibody treatment, 
compared with Bregs group.  
•Bregs promoted HCC progression through CD40-CD154 interaction in vivo and in vitro. 
•Suppression of Bregs may be an appealing therapeutic strategy in the treatment of HCC. 
 
(Shao Y, et al, Cancer Letters, 2014. 264-272) 
